Is MMED a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Mind Medicine (MMED) rests on A full US product cycle: MiniMed has lost US share to Insulet's Omnipod and Tandem over several years. The bear case rests on miniMed is unprofitable on a GAAP basis (trailing net loss about $314 million, operating cash flow negative) and has a thin cash balance of about $207 million on its latest balance sheet, so execution on the margin plan matters. Analysts covering it publish targets from $15.00 to $30.00 against a $17.49 price, so even the professionals disagree by 60% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
MiniMed Group is Medtronic's former Diabetes business, headquartered in Northridge, California, with about 8,000 employees and products sold in about 80 countries. It makes automated insulin delivery systems (the MiniMed 780G, and since 2026 the smaller MiniMed Flex), MiniMed Go smart insulin pens, Simplera continuous glucose monitors, and sells the Instinct sensor made by Abbott, all tied together by its own algorithms and app. CEO Que Dallara leads the company. The separation ran in two steps. On March 9, 2026 MiniMed completed an IPO of 28 million shares at $20 each while Medtronic kept the large majority. On October 15, 2026 Medtronic completed an exchange offer in which its shareholders swapped about 55 million Medtronic shares for about 252.8 million MiniMed shares; the offer was 5.4 times subscribed, and Medtronic no longer owns any MiniMed stock. MiniMed named a reshaped eight-member board the next day. Financially, MiniMed booked about $2.96 billion of sales in its fiscal year ended April 2026 with a net loss of about $331 million, and trailing revenue has reached about $3.22 billion. Its fiscal first quarter of 2027 (ended July 31, 2026) brought $843 million of sales, up 16.6% reported (low double digits excluding an extra week), with US sales up 13% and international up 18%. Gross margin runs near 57% while operating margin is close to zero, so the investment case rests on growth and scale bringing profits through.
The bull case: what would have to be true for $30.00
The most optimistic published target on MMED is $30.00, +71.5% from the $17.49 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. A full US product cycle
MiniMed has lost US share to Insulet's Omnipod and Tandem over several years. The US launch of MiniMed Flex, with Simplera and then Abbott's Instinct sensor, lifted US new pumps sold by more than 20% in the July quarter and extended Medicare coverage. The MiniMed Fit patch pump was submitted to the FDA with a full US launch expected in summer 2027, and the Vivera fully closed-loop algorithm finished enrollment in its registrational trial for a planned second-half 2027 US launch.
2. International growth engine
About 70% of sales come from outside the US, where the 780G is a leading automated insulin delivery system. International sales grew 18% in the July quarter on Simplera capacity expansion and the Instinct sensor launch, and MiniMed Flex received its CE Mark with a European launch expected in November 2026.
3. Margin expansion as a standalone company
Management guides fiscal 2027 organic growth of about 10.5% (raised from about 10%) and an adjusted EBITDA margin of about 16%. Analysts expect EPS of about $0.70 this fiscal year after a loss last year, which puts the stock near 25 times forward earnings. Delivering that swing depends on sensor costs, the stand-up costs of leaving Medtronic and pricing.
4. Sensors and recurring revenue
Pumps sell every few years, but sensors and supplies recur. Worldwide CGM attachment reached about 69%, up about a point in a quarter, and a next-generation extended-wear MiniMed sensor won FDA approval to begin a US registrational trial. Higher attachment shifts the mix toward recurring revenue.
The bear case: what would have to be true for $15.00
The most pessimistic published target is $15.00, -14.2% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Mind Medicine is worth if the risks below bite instead of the drivers above.
MiniMed is unprofitable on a GAAP basis (trailing net loss about $314 million, operating cash flow negative) and has a thin cash balance of about $207 million on its latest balance sheet, so execution on the margin plan matters. Competition is intense: Insulet, Tandem, Dexcom and Abbott each have strong positions, and GLP-1 drugs could change how many type 2 patients need intensive insulin therapy. MiniMed depends partly on Abbott for a sensor. The company has a history of FDA warning letters and recalls under Medtronic. New standalone costs and transition agreements with Medtronic add uncertainty. Supply overhang is a near-term risk: about 253 million shares reached former Medtronic holders on October 15, 2026, and the stock fell about 19% in the month before the exchange closed.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding MMED already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on MMED
15 analysts cover MMED, with an average target of $25.00 (+42.9% against $17.49) and a split of 12 buy, 3 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the MMED forecast and price target page.
How is MMED valued? (as of October 2026)
Snapshot for MMED as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$3.2 billion; latest quarter up ~17% year over year
- Gross / operating margin: ~57% / ~0.5%
- Net income (TTM): ~-$314 million; EPS about -$1.53
- P/E (forward): ~25x (forward EPS ~$0.69)
- Price to sales: ~1.5x
- Market cap: ~$4.9 billion (share price ~$17.58)
- FY2027 guidance: ~10.5% organic growth, ~16% adjusted EBITDA margin
- Dividend: None
At about 1.5 times sales, MiniMed trades at a steep discount to faster-growing, profitable diabetes-device peers, a gap that reflects its GAAP losses, its recent US share losses and the overhang from Medtronic's exit. On forward earnings the multiple is about 25x. The 15 covering analysts rate it a buy with a mean target near $25, and Rothschild & Co Redburn initiated at buy with a $30 target on October 13, 2026.
How do you decide if MMED is a buy?
Rather than asking whether MMED is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MMED indirectly through an index or sector ETF before adding more.
What would change your mind on MMED
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: A full US product cycle stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: miniMed is unprofitable on a GAAP basis (trailing net loss about $314 million, operating cash flow negative) and has a thin cash balance of about $207 million on its latest balance sheet, so execution on the margin plan matters fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the MMED stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MMED against your real portfolio and see your actual exposure before deciding.
Investing in Mind Medicine with AI
Connect the broker you already use and ask Walnut's AI how MMED fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is MMED a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on A full US product cycle, with revenue (ttm) at ~$3.2 billion; latest quarter up ~17% year over year. The bear case rests on miniMed is unprofitable on a GAAP basis (trailing net loss about $314 million, operating cash flow negative) and has a thin cash balance of about $207 million on its latest balance sheet, so execution on the margin plan matters. Analysts covering it are spread from $15.00 to $30.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell MMED?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. MiniMed is unprofitable on a GAAP basis (trailing net loss about $314 million, operating cash flow negative) and has a thin cash balance of about $207 million on its latest balance sheet, so execution on the margin plan matters. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $15.00, -14.2% from the $17.49 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for MMED?
+
A full US product cycle. MiniMed has lost US share to Insulet's Omnipod and Tandem over several years. The most optimistic analyst target on MMED is $30.00, +71.5% from the $17.49 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for MMED?
+
MiniMed is unprofitable on a GAAP basis (trailing net loss about $314 million, operating cash flow negative) and has a thin cash balance of about $207 million on its latest balance sheet, so execution on the margin plan matters. Competition is intense: Insulet, Tandem, Dexcom and Abbott each have strong positions, and GLP-1 drugs could change how many type 2 patients need intensive insulin therapy. MiniMed depends partly on Abbott for a sensor. The company has a history of FDA warning letters and recalls under Medtronic. New standalone costs and transition agreements with Medtronic add uncertainty. Supply overhang is a near-term risk: about 253 million shares reached former Medtronic holders on October 15, 2026, and the stock fell about 19% in the month before the exchange closed. The most pessimistic published target is $15.00, -14.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Mind Medicine do?
+
Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company building treatments for brain-health and psychiatric disorders from psychedelic and related compounds.
What would have to change for MMED to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (A full US product cycle) stalling in the reported numbers rather than in the narrative, the risk above (miniMed is unprofitable on a GAAP basis (trailing net loss about $314 million, operating cash flow negative) and has a thin cash balance of about $207 million on its latest balance sheet, so execution on the margin plan matters) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does MiniMed (MMED) do?
+
MiniMed makes diabetes technology: insulin pumps with automated insulin delivery (MiniMed 780G, MiniMed Flex), continuous glucose monitors (Simplera, and the Abbott-made Instinct sensor), MiniMed Go smart insulin pens, and the algorithms and app that connect them. It was Medtronic's Diabetes business until its 2026 separation and serves people with diabetes in about 80 countries.
Is MMED the same company as Mind Medicine (MindMed)?
+
No. MMED was once associated with Mind Medicine (MindMed), the psychedelic-medicine developer, through its earlier Canadian listing. MindMed traded on Nasdaq as MNMD and in January 2026 rebranded to Definium Therapeutics under the ticker DFTX. In 2026 the Nasdaq symbol MMED went to MiniMed Group, the Medtronic diabetes spin-off, which is what this page covers.
When did MiniMed become a separate company?
+
MiniMed completed an IPO of 28 million shares at $20 on March 9, 2026, with Medtronic keeping a majority stake. On October 15, 2026 Medtronic completed an exchange offer that swapped about 55 million Medtronic shares for about 252.8 million MiniMed shares, leaving Medtronic with no MiniMed stock. The offer was 5.4 times subscribed.
Walnut is informational, not investment advice, and gives no verdict on MMED. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.